View More Recent Stories

Feb 5, 2025 10:19AM TD Cowen Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
Feb 5, 2025 08:23AM EyePoint Pharmaceuticals' (EYPT) decline "makes no sense", says Cantor Fitzgerald
Feb 5, 2025 07:01AM EyePoint Pharmaceuticals (EYPT) Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
Jan 13, 2025 07:07AM EyePoint Pharmaceuticals (EYPT) Provides Company Update and Anticipated Development Milestones for 2025
Jan 8, 2025 07:02AM EyePoint Pharmaceuticals (EYPT) Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors
Jan 7, 2025 05:01AM Citi Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Buy
Dec 4, 2024 07:03AM EyePoint Pharmaceuticals (EYPT) Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration
Nov 11, 2024 08:40AM EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $33 at Baird
Nov 11, 2024 07:24AM EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $22 at H.C. Wainwright
Nov 7, 2024 05:14PM EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 2c
Oct 30, 2024 06:07AM EyePoint Pharmaceuticals (EYPT) Prices Upsized 12.73M Share Offering at $11/sh
Oct 28, 2024 05:14PM EyePoint Pharmaceuticals (EYPT) Announces Proposed $100M Share Offering
Oct 28, 2024 02:23PM Guggenheim Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
Oct 28, 2024 10:59AM Laidlaw Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
Oct 28, 2024 07:00AM EyePoint Pharmaceuticals (EYPT) Reports Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU
Oct 25, 2024 08:06AM H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
Oct 25, 2024 05:52AM CapitalOne Reiterates Underweight Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
Oct 24, 2024 02:34PM Laidlaw Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
Oct 24, 2024 07:02AM EyePoint Pharmaceuticals (EYPT) Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration
Sep 4, 2024 07:01AM EyePoint Pharmaceuticals (EYPT) Appoints Fred Hassan to its Board
Aug 28, 2024 02:16AM Jefferies Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Buy
Aug 7, 2024 07:07AM EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 4c
Jun 27, 2024 12:30PM TD Cowen Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
Jun 27, 2024 06:38AM H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
Jun 26, 2024 03:45PM Laidlaw Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
Jun 26, 2024 08:01AM EyePoint Pharmaceuticals (EYPT) to Highlight DURAVYUTM Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
View More Recent Stories